文献速递真实世界研究与卫生经济流行病学与生物统计

南非婴儿早期HIV诊断中确认检测的成本效果分析

The value of confirmatory testing in early infant HIV diagnosis programmes in South Africa: A cost-effectiveness analysis.
PubMed 文献 · PLoS Med · 2017-11-21

该研究使用CEPAC-Pediatric模型模拟南非6周龄HIV暴露婴儿的早期诊断,比较有无疑似阳性确认检测的策略。结果显示无确认检测时每1000例启动ART的婴儿中128例为假阳性,确认检测可降至1例,且总成本更低(1790 vs 1830美元/婴儿),确认检测可节省成本。

要点

  • 无确认检测时每1000例启动ART中128例为假阳性,确认检测降至1例。
  • 确认检测使每婴儿总成本从1830美元降至1790美元,具成本节省。
  • 只要NAAT成本不超过400美元,确认检测仍保持成本节省。

核心结论

  • 在MTCT率与南非相似的环境中,无确认检测时超过10%启动ART的婴儿可能为假阳性诊断。
  • 确认检测可防止不恰当的HIV诊断,具有成本节省效果,应被所有EID项目采纳。

研究设计与样本

  • 使用CEPAC-Pediatric模型模拟6周龄HIV暴露婴儿的EID检测,比较无和有确认检测两种策略。
  • 假设NAAT成本25美元、特异性99.6%、敏感性100%(孕期或检测前至少4周感染),12个月MTCT率4.9%,检测 uptake、结果返回和ART启动率达指南一致的100%。

主要发现

  • 无确认检测时每1000例ART启动中128例为假阳性诊断,有确认检测时为1例。
  • 两种策略下HIV感染婴儿预期寿命均为26.2年,所有HIV暴露婴儿均为61.4年,真正感染婴儿的临床结局无差异。
  • 有确认检测的总成本为每检测婴儿1790美元,无确认检测为1830美元,确认检测节省成本。

关键数值与推荐

  • NAAT成本25美元、特异性99.6%、敏感性100%(孕期或检测前至少4周感染)、12个月MTCT率4.9%。
  • 确认检测在NAAT成本不超过400美元或假阳性婴儿3个月内被确认未感染并停止ART时仍保持成本节省。

临床怎么用

  • 在EID项目中实施确认检测以避免假阳性诊断和不必要的ART。
  • 确认检测可节省HIV相关医疗成本。

局限性

  • 模型数据存在不确定性,已通过敏感性和不确定性分析考察。
  • 未纳入假阳性诊断后接受ART的HIV未感染婴儿的临床危害(如药物毒性),纳入后可能进一步增加确认检测的价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The specificity of nucleic acid amplification tests (NAATs) used for early infant diagnosis (EID) of HIV infection is <100%, leading some HIV-uninfected infants to be incorrectly identified as HIV-infected. The World Health Organization recommends that infants undergo a second NAAT to confirm any positive test result, but implementation is limited. Our objective was to determine the impact and cost-effectiveness of confirmatory HIV testing for EID programmes in South Africa. METHOD AND FINDINGS: Using the Cost-effectiveness of Preventing AIDS Complications (CEPAC)-Pediatric model, we simulated EID testing at age 6 weeks for HIV-exposed infants without and with confirmatory testing. We assumed a NAAT cost of US$25, NAAT specificity of 99.6%, NAAT sensitivity of 100% for infants infected in pregnancy or at least 4 weeks prior to testing, and a mother-to-child transmission (MTCT) rate at 12 months of 4.9%; we simulated guideline-concordant rates of testing uptake, result return, and antiretroviral therapy (ART) initiation (100%). After diagnosis, infants were linked to and retained in care for 10 years (false-positive) or lifelong (true-positive). All parameters were varied widely in sensitivity analyses. Outcomes included number of infants with false-positive diagnoses linked to ART per 1,000 ART initiations, life expectancy (LE, in years) and per-person lifetime HIV-related healthcare costs. Both without and with confirmatory testing, LE was 26.2 years for HIV-infected infants and 61.4 years for all HIV-exposed infants; clinical outcomes for truly infected infants did not differ by strategy. Without confirmatory testing, 128/1,000 ART initiations were false-positive diagnoses; with confirmatory testing, 1/1,000 ART initiations were false-positive diagnoses. Because confirmatory testing averted costly HIV care and ART in truly HIV-uninfected infants, it was cost-saving: total cost US$1,790/infant tested, compared to US$1,830/infant tested without confirmatory testing. Confirmatory testing remained cost-saving unless NAAT cost exceeded US$400 or the HIV-uninfected status of infants incorrectly identified as infected was ascertained and ART stopped within 3 months of starting. Limitations include uncertainty in the data used in the model, which we examined with sensitivity and uncertainty analyses. We also excluded clinical harms to HIV-uninfected infants incorrectly treated with ART after false-positive diagnosis (e.g., medication toxicities); including these outcomes would further increase the value of confirmatory testing. CONCLUSIONS: Without confirmatory testing, in settings with MTCT rates similar to that of South Africa, more than 10% of infants who initiate ART may reflect false-positive diagnoses. Confirmatory testing prevents inappropriate HIV diagnosis, is cost-saving, and should be adopted in all EID programmes.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Dunning L, Francke JA, Mallampati D, et al. The value of confirmatory testing in early infant HIV diagnosis programmes in South Africa: A cost-effectiveness analysis. PLoS Med. 2017. PMID: 29161262. doi:10.1371/journal.pmed.1002446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。